Comparative Pharmacokinetics and Insulin Action for Three Rapid-Acting Insulin Analogs Injected Subcutaneously With and Without Hyaluronidase
| Autor: | Elizabeth A. Ludington, Linda Morrow, Douglas B. Muchmore, Marcus Hompesch, Daniel Vaughn |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male medicine.medical_specialty Endocrinology Diabetes and Metabolism medicine.medical_treatment Injections Subcutaneous Hyaluronoglucosaminidase Absorption (skin) Pharmacokinetics Double-Blind Method Hyaluronidase Internal medicine Diabetes mellitus Internal Medicine Medicine Humans Hypoglycemic Agents Insulin Drug Interactions Original Research Advanced and Specialized Nursing Cross-Over Studies business.industry Insulin Short-Acting Clinical Care/Education/Nutrition/Psychosocial Research medicine.disease Crossover study Endocrinology Recombinant Human Hyaluronidase Rapid-acting insulin Female business medicine.drug |
| Zdroj: | Diabetes Care |
| ISSN: | 1935-5548 0149-5992 |
| Popis: | OBJECTIVE To compare the pharmacokinetics and glucodynamics of three rapid-acting insulin analogs (aspart, glulisine, and lispro) injected subcutaneously with or without recombinant human hyaluronidase (rHuPH20). RESEARCH DESIGN AND METHODS This double-blind six-way crossover euglycemic glucose clamp study was conducted in 14 healthy volunteers. Each analog was injected subcutaneously (0.15 units/kg) with or without rHuPH20. RESULTS The commercial formulations had comparable insulin time-exposure and time-action profiles as follows: 50% exposure at 123–131 min and 50% total glucose infused at 183–186 min. With rHuPH20, the analogs had faster yet still comparable profiles: 50% exposure at 71–79 min and 50% glucose infused at 127–140 min. The accelerated absorption with rHuPH20 led to twice the exposure in the first hour and half the exposure beyond 2 h, which resulted in 13- to 25-min faster onset and 40- to 49-min shorter mean duration of insulin action. CONCLUSIONS Coinjection of rHuPH20 with rapid-acting analogs accelerated insulin exposure, producing an ultra-rapid time-action profile with a faster onset and shorter duration of insulin action. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|